Publication:
Preliminary pharmaceutical development of antimalarial-antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas

dc.contributor.authorAlexandra Gauberten_US
dc.contributor.authorTina Kaussen_US
dc.contributor.authorMathieu Marchivieen_US
dc.contributor.authorBoubakar B. Baen_US
dc.contributor.authorMartine Lembegeen_US
dc.contributor.authorFawaz Fawazen_US
dc.contributor.authorJean Michel Boironen_US
dc.contributor.authorXavier Lafargeen_US
dc.contributor.authorNiklas Lindegardhen_US
dc.contributor.authorJean Louis Fabreen_US
dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.authorPiero L. Olliaroen_US
dc.contributor.authorPascal Milleten_US
dc.contributor.authorKaren Gaudinen_US
dc.contributor.otherDeveloppements Analytiques et Pharmaceutiques Appliques aux Maladies Negligees et Aux Contrefaconsen_US
dc.contributor.otherUniversite de Bordeauxen_US
dc.contributor.otherEtablissement Francais du Sangen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherOTECI (Office Technique d'Etude et de Coopération Internationale)en_US
dc.contributor.otherNuffield Department of Clinical Medicineen_US
dc.contributor.otherOrganisation Mondiale de la Santeen_US
dc.date.accessioned2018-11-09T03:10:05Z
dc.date.available2018-11-09T03:10:05Z
dc.date.issued2014-07-01en_US
dc.description.abstractArtemether (AM) plus azithromycin (AZ) rectal co-formulations were studied to provide pre-referral treatment for children with severe febrile illnesses in malaria-endemic areas. The target profile required that such product should be cheap, easy to administer by non-medically qualified persons, rapidly effective against both malaria and bacterial infections. Analytical and pharmacotechnical development, followed by in vitro and in vivo evaluation, were conducted for various AMAZ coformulations. Of the formulations tested, stability was highest for dry solid forms and bioavailability for hard gelatin capsules; AM release from AMAZ rectodispersible tablet was suboptimal due to a modification of its micro-crystalline structure. © 2014 The Authors.en_US
dc.identifier.citationInternational Journal of Pharmaceutics. Vol.468, No.1-2 (2014), 55-63en_US
dc.identifier.doi10.1016/j.ijpharm.2014.04.023en_US
dc.identifier.issn18733476en_US
dc.identifier.issn03785173en_US
dc.identifier.other2-s2.0-84899424141en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/34901
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84899424141&origin=inwarden_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titlePreliminary pharmaceutical development of antimalarial-antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areasen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84899424141&origin=inwarden_US

Files

Collections